Recently, an advisory committee of the U.S. Food and Drug Administration voted in favor of requiring additional trial data in order for a China-trialed medicine to obtain FDA approval. This decision could have major implications for future regulatory approval applications for medicines developed in China. The FDA's positions and the considerations of the committee members are summarized below.
This post is for subscribers only
Already have an account? Sign in
You've successfully subscribed to China Trade Monitor
Great! Next, complete checkout for full access to China Trade Monitor
Welcome back! You've successfully signed in.
Unable to sign you in. Please try again.
Success! Your account is fully activated, you now have access to all content.
Error! Stripe checkout failed.
Success! Your billing info is updated.
Error! Billing info update failed.